Mirada Medical Software Selected for Tumor Metrics at MD Anderson Cancer Center
Published: Nov 23, 2011
OXFORD, UK--(Marketwire - November 23, 2011) - Mirada Medical announced that it has been selected to deliver its advanced XD3 image review and analysis software to The University of Texas MD Anderson Cancer Center in Houston. Mirada's latest XD3 software release includes volumetric CT segmentation in addition to tools for CT/PET and MR/PET to facilitate both anatomical and functional response tracking.
Mirada XD3 provides powerful tools and efficient workflows for quantification and tracking of findings in an unlimited number of studies for all major modalities including CT, MR, CT/PET and MR/PET.
"We are delighted that MD Anderson Cancer Center has chosen Mirada software." stated Dr. Timor Kadir, Chief Scientist at Mirada Medical. "With tools such as CT segmentation, auto-alignment, and built-in findings tracking, our latest release offers the power to handle the growing imaging volumes and complexity in trials."
About Mirada Medical
Mirada Medical is an internationally recognised brand in advanced medical imaging. The company develops high value clinical software applications, which are used across diagnostic radiology, nuclear medicine, radiation oncology, tumor board and elsewhere.
Mirada specializes in simplifying technically complex image processing tasks, allowing clinicians to more confidently diagnose disease, assess response to treatment and plan radiation therapy or surgical intervention.
Mirada was originally spun out of the University of Oxford. The company's technologies are, to this day, developed by a team of dedicated engineers and world-renowned scientists working out of Oxford, England.
Mirada's products have been designed to ease the deployment of these powerful technologies into any hospital or imaging center workflow. Mirada's applications can be delivered using thin client or cloud based architectures, or licensed on a floating or per workstation basis. Most recently, Mirada has focused on the development of disease specific solutions for use across departments working with patients to fight cancer. In particular, Mirada's powerful image registration technologies have been tuned to the needs of radiation oncology, and quantification technologies have been redefined to optimize support for standard protocols such as RECIST and PERCIST. In addition, powerful imaging solutions have been introduced to support better collaborative working, in particular in the context of a rich web-based viewer for referring physicians and a robust solution for presentation of images at multidisciplinary meetings such as tumor board.
Mirada Medical, Mirada XD3, Caseaccess and Casemeeting are all trademarks of Mirada Medical Ltd.
For more information, visit www.mirada-medical.com
For more information, please contact:
US/Worldwide: Robert Ripley
tel: (440) 591-8638
Oxford Center for Innovation
New Road, Oxford
Tel: +44(0)1865 261410